Neurogene Inc.
NGNEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Neurogene Inc. (NGNE) is listed under Biotechnology. With a market capitalization of $772.4M, it sits in small-cap territory. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Market Cap
$772.4M
Beta
1.96
P/E (TTM)
—
P/E (Fwd)
-7.46
EPS (TTM)
$-5.04
EPS (Fwd)
$-5.18
ROE
-45.3%
ROA
-28.0%
Cash
$225.4M
Total Debt
$8.3M
Free CF
-$48.1M
52W Change
100.5%
Annual Financials
Cash vs Debt
Where NGNE stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, NGNE finished 35.73% above its 150-day moving average ($27.90) and 46.10% above its 200-day moving average ($25.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NGNE overbought or oversold?
At the September 2, 2026 close, NGNE's RSI(14) was 52.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $225.4M in cash comfortably exceeding the $8.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$48.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -45.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.96 means NGNE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, NGNE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Neurogene Inc.'s trajectory.